Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground

Executive Summary

As Gilead’s ASK1 inhibitor nears Phase III, Intercept may be plagued by slower-than-expected enrollment of its Phase III trial for Ocaliva. A recent Biomedtracker survey finds liver docs may be more positively inclined toward the Gilead candidate.


Related Content

Gilead’s FXR Agonist Posts Questionable Results In NASH, But Offers Hope In PSC
Pfizer/Novartis Collaboration Brings Combined Strength To NASH Development
New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib
How Do You Solve A Problem Like Biopsy In Alcohol-Associated Liver Disease?
Common Treatment May Be Removed In Alcoholic Hepatitis Trials
Madrigal's Early Phase IIb NASH Data Show Clinically Meaningful Fat Reduction
Gilead Plays Up Its Strength As Market Awaits Business Development Moves
Genfit Says Safety/Tolerability Will Give Elafibranor An Edge In NASH
The NASH Pipeline: Replete With Targets And New Compounds
Intercept quiet on NASH safety data disclosure concerns


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts